Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

Annals of Surgical Oncology

Volumn 22, Issue 4, 2015, Pages 1153-1159

  Blazer, Marlo ^a   Wu, Christina ^a   Goldberg, Richard M ^a   Phillips, Gary ^a   Schmidt, Carl ^a   Muscarella, Peter ^a   Wuthrick, Evan ^a   Williams, Terrence M ^a   Reardon, Joshua ^a   Christopher Ellison, E ^a   Bloomston, Mark ^a   Bekaii Saab, Tanios ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; FOSAPREPITANT; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PALONOSETRON; PEGFILGRASTIM; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; PLATINUM COMPLEX;

ABSCESS; ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE LEAKAGE; BOLUS INJECTION; BORDERLINE RESECTABLE PANCREATIC CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHOLANGITIS; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; LOCALLY ADVANCED PANCREATIC CANCER; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PNEUMONIA; PROGRESSION FREE SURVIVAL; REOPERATION; RETROSPECTIVE STUDY; STOMACH PERFORATION; SURGICAL INFECTION; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; CANCER STAGING; FOLLOW UP; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84923848673     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4225-1     Document Type: Article

References (17)

1. Seigel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10–29.
2. Poplin E, Feng Y, Berlin J, Rothenber ML, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-min infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778–85.
3. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68:809–16.
4. Mukherjee S, Hurt C, Griffith G, et al. SCALOP: Results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LANPC). J Clin Oncol. 2012;30(Suppl 34). Abstract LBA146.
5. Smeenk HG, Incrocci L, Kazemier G, et al. Adjuvant 5-FU-based chemoradiotheray for patients undergoing R1/R2 resections for pancreatic cancer. Dig Surg. 2005;22:321–8.
6. Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer: local or hepatic? Hepatogastroenterology. 1993;40:382–7.
7. Kleef J, Reiser C, Hinz U, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg. 2007:245;566–72.
8. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.
9. Konstantinidis IT, Warshaw AL, Allen JN, et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resctions versus locally advanced unresectable tumors? What is a “true” R0 resection? Ann Surg. 2013;257:731–6.
10. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
11. Callery MP, Chang KJ, Fishman EK, Talamonit MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727–33.
12. Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68:3:801–8.
13. Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgan CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplain with radiation therapy in patients with pancreatic cancer. Cancer. 2013. Presented in part at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 20–21 January, 2011, San Francisco, CA, USA.
14. Gillen S, Schuster T, Meyer zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.
15. Hosein PJ, Macintyre J, Kawamura C. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199. doi:10.1186/1471-2407-12-199.
16. Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18:543–8.
17. Moureau-Zabotto L, Phelip J-M, Afchain P, Mineur L, et al. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a groupe coordinateur multidisciplinaire en oncologie phase II study. J Clin Oncol. 2008;26:1080–5.